Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
← catalyst calendarSponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
328estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-21 | actual | When the study began enrolling |
| Primary completion | 2025-10-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pancreatic Cancer
Interventions
- Biological: N-803
- Drug: Aldoxorubicin HCl
- Biological: PD-L1 t-haNK
- Drug: Nab-paclitaxel
- Drug: Gemcitabine
- Drug: Cyclophosphamide
- Drug: 5-Fluorouracil
- Drug: Leucovorin
- Procedure: SBRT
- Drug: Irinotecan liposome
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured 8 weeks
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed